Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease
Authors:
- Jagan A. PillaiJPJagan A. Pillai
- For The Alzheimer’s Disease Neuroimaging InitiativeFIFor The Alzheimer’s Disease Neuroimaging Initiative
Open Access
- 4 July 2019
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (7) , 1248-1262
Abstract
Objective: To determine the key inflammatory pathways that are activated in the peripheral and CNS compartments at the mild cognitive impairment (MCI) stage of Alzheimer’s disease (AD).Methods: A cross‐sectional study of patients with clinical and biomarker characteristics consistent with MCI‐AD in a discovery cohort, with replication in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. Inflammatory analytes were measured in the CSF and plasma with the same validated multiplex analyte platform in both cohorts and correlated with AD biomarkers (CSF Aβ42, total tau (t‐tau), phosphorylated tau (p‐tau) to identify key inflammatory pathway activations. The pathways were additionally validated by evaluating genes related to all analytes in coexpression networks of brain tissue transcriptome from an autopsy confirmed AD cohort to interrogate if the same pathway activations were conserved in the brain tissue gene modules.Results: Analytes of the tumor necrosis factor (TNF) signaling pathway (KEGG ID:4668) in the CSF and plasma best correlated with CSF t‐tau and p‐tau levels, and analytes of the complement and coagulation pathway (KEGG ID:4610) best correlated with CSF Aβ42 levels. The top inflammatory signaling pathways of significance were conserved in the peripheral and the CNS compartments. They were also confirmed to be enriched in AD brain transcriptome gene clusters.Interpretation: A cell‐protective rather than a proinflammatory analyte profile predominates in the CSF in relation to neurodegeneration markers among MCI‐AD patients. Analytes from the TNF signaling and the complement and coagulation pathways are relevant in evaluating disease severity at the MCI stage of AD.Keywords
Funding Information
- National Institute on Aging (K23AG055685-01, R01AG022304-12, U01 AG024904)
- Alzheimer's Association (2014-NIRG-305310)
- U.S. Department of War (W81XWH-12-2-0012)
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Eisai
- Elan
- Eli Lilly and Company
- Roche
- Genentech
- Fujirebio Europe
- GE Healthcare
- Johnson and Johnson
- Merck
- Meso Scale Diagnostics
- Novartis
- Pfizer
- Takeda Pharmaceutical Company
- Health Research
- National Institutes of Health
- Northern California Institute for Research and Education
- University of Southern California
This publication has 49 references indexed in Scilit:
- GO-Elite: a flexible solution for pathway and ontology over-representationBioinformatics, 2012
- Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical LiteratureCold Spring Harbor Perspectives in Medicine, 2011
- YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's DiseaseBiological Psychiatry, 2010
- An Integrative -omics Approach to Identify Functional Sub-Networks in Human Colorectal CancerPLOS Computational Biology, 2010
- Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little?Neuron, 2009
- Systemic inflammation and disease progression in Alzheimer diseaseNeurology, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Discovery and Scoring of Protein Interaction Subnetworks Discriminative of Late Stage Human Colon CancerMolecular & Cellular Proteomics, 2009
- The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-reviewBMC Neuroscience, 2008
- Network‐based classification of breast cancer metastasisMolecular Systems Biology, 2007